Alphyn Biologics
Develops first-in-class, multi-target therapeutics for atopic dermatitis and other severe and common skin diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $5.2m | Early VC |
| Total Funding | 000k | ||
Related Content
Alphyn Biologics is a life science company focused on developing a new class of drugs called Multi Target therapies to treat severe and prevalent skin diseases. The company leverages its patent-pending AB 101 platform biomaterial, which contains multiple bioactives, to address complex skin conditions. Alphyn's primary target is Atopic Dermatitis (AD), also known as Eczema, a condition that affects millions globally and is notoriously difficult to treat. The AB 101 platform aims to tackle all aspects of AD, including immune response issues like inflammation and itch, as well as bacterial problems such as infections and MRSA drug-resistant bacteria.
Alphyn Biologics operates in the pharmaceutical and biotechnology market, serving patients with severe skin conditions. The company follows a business model centered on research and development, aiming to bring innovative treatments to market through FDA approval processes. Revenue is generated through the commercialization of its proprietary therapies.
Keywords: Multi Target therapies, AB 101 platform, Atopic Dermatitis, Eczema, skin diseases, bioactives, inflammation, itch, MRSA, biotechnology.